Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

neuroprotective agents (neurodegenerative diseases)

Home Drugsneuroprotective agents (neurodegenerative diseases)

neuroprotective agents (neurodegenerative diseases)

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Neuroprotective agents for treatment of neurodegenerative diseases
Applicant: UNIV WAYNE STATEPriority: 2019
US
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
Applicant: KOVACH JOHN SPriority: 2009
US
4 publications
DONECOPRIDE AND FLUCOPRIDE AS NEUROPROTECTIVE AGENTS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
Applicant: UNIV CAENPriority: 2018
EP
Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases
Applicant: DUTTA ALOKE KPriority: 2010
US
2 publications
Neuroprotective agents
Applicant: YALPANI MANSSURPriority: 2003
US
Neuroprotectant methods, compositions, and screening methods thereof
Applicant: ARUOMA OKEZIE IPriority: 2006
US
Compounds advantageous in the treatment of central nervous system diseases and disorders
Applicant: AURIMMED PHARMA INCPriority: 2022
US
Compounds advantageous in the treatment of central nervous system diseases and disorders
Applicant: AURIMMED PHARMA INCPriority: 2015
US